Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments

• Format: eBook
• Language: English
• Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
• Subjects: Medicine; adjuvant chemotherapy; biomarker; chemotherapy; daily practice; DNA polymerase beta; docetaxel; EGFR-TKI; endocrine disorders; epidermal growth factor receptor; Expanded Access Program; FDG-PET; genomic diagnosis; glucose transporter 1; HIP1R; immune checkpoint inhibitor; immune checkpoint inhibitors; immune-related adverse events; immunotherapy; interstitial lung disease; KRAS; lung cancer; lung neoplasms; meta-analysis; metastasis; methylation; multiple cancers; mutation; network meta-analysis; nivolumab; non-small cell lung cancer; non-small-cell lung cancer; nonsmall cell lung cancer; NSCLC; nucleotide-diphosphate kinase; oligometastasis; osimertinib; PD-1; PD-1 blockade; PD-1 inhibitors; PD-L1; PD-L1 expression; PD-L1 inhibitors; phase I/II trial; platinum-based first-line; predictive biomarker; previously treated patients; prognosis; prognostic factor; prognostic factors; pulmonary fibrosis; pulmonary pleomorphic carcinoma; RAD51B methylation; radiology and other imaging; real-world data; rechallenge; recurrence; responsiveness; retrospective analysis; RUNX1; S-1; salvage surgery; sequencing; stage IIIA-N2; surgery; survival; T790M; targeted therapy; TP53 mutations; tumor-bearing patients; tyrosine kinase inhibitors; unresectable; β-catenin
• Online Access: Open Access: DOAB: description of the publication; Open Access: DOAB, download the publication

 Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (EGFR) mutations. This discovery opened the door for biomarker-based treatment strategies. Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. In recent years, many mechanisms of resistance to EGFR-TKI have been elucidated; a mutation in the T790M gene at exon 20 is found in half of the resistant cases. Hence, osimertinib, which specifically inhibits EGFR despite this T790M gene mutation, was developed to achieve long-term progression-free survival. Other driver mutations that are similar to the EGFR mutation were discovered, including the EML4-ALK fusion gene (discovered in 2007), ROS1 gene, and BRAF gene mutations. The TKIs for each of these fusion genes were developed and are used as therapeutic agents. Another advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. Four PD-1/PD-L1 inhibitors, including nivolumab, are currently available for treatment of lung cancer. These drugs prevent an escape from the cancer immunity cycle. This ensures that cancer cells will express cancer antigens, causing an anticancer immune response. Due to cancer immunotherapy, long-term survival is possible. The biomarker development for cancer immunotherapy and its side effects are actively being studied.